SIMONA RUXANDRA VOLOVAT, CRISTIAN CONSTANTIN VOLOVAT, LUCIAN MIRON, DRAGOS VIOREL SCRIPCARIU, ELENA DANIELA SEMEN, MANUELA CIOCOIU MAGNESIUM SUPPLEMENTATION AND CISPLATIN-INDUCED RENAL IMPAIRMENT IN CANCER PATIENTS Cisplatin-induced renal dysfunction represents a limiting complication in patients receiving chemotherapy. Various preventive strategies have been implemented and various guidelines recommend magnesium supplementation. Twenty-four patients receiving cisplatin regimens and magnesium supplementation were assessed before, during and at the end of chemotherapy cycles. Renal impairment is generally expected to occur in up to 75% of the patients; our study reports this side effect in 20.8%, with a median decrease in the creatinine clearance of 11.2%.
Keywords: renal dysfunction, cisplatin, hypomagnesemia, cancer